More recently in 2020, scientists and clinicians investigating GS010 (lenadogene nolparvovec) reported improvements in visual acuity after intravitreal injection (IVT) of AAV2.ND4 to patients diagnosed with Leber hereditary optic neuropathy (LHON), a mitochondrial genetic eye disorder caused by the m.11778 G > A point mutation in the MT-ND4 gene, which is characterised by rapid loss of retinal ganglion cell (RGC) function [4]. The gene discussed is MT-ND4; the disease is Leber hereditary optic neuropathy.